June 3, 2022

Niall J. Lennon, Ph.D.
Institute Scientist and Sr. Director
Clinical Research Sequencing Platform (CRSP), LLC at the Broad Institute of MIT and Harvard
320 Charles Street
Cambridge, MA 02141

Device: CRSP SARS-CoV-2 Real-time Reverse Transcriptase (RT)-PCR Diagnostic Assay (Version 3)

EUA Number: EUA210089

Company: Clinical Research Sequencing Platform (CRSP), LLC at the Broad Institute of MIT and Harvard

Indication: This test is authorized for the following indications for use:

Qualitative detection of nucleic acid from SARS-CoV-2 in dry anterior nasal swabs from individuals suspected of COVID-19 by their healthcare provider.

This test is also authorized for the qualitative detection of nucleic acid from SARS-CoV-2 in dry anterior nasal swab specimens collected using the CRSP Self-Swab kit, by individuals 18 years of age and older (self-collected), 14 years and older (self-collected under adult supervision), or 2 years and older (collected with adult assistance) suspected of COVID-19 by their healthcare provider and when determined to be appropriate by the healthcare provider.

This test is also authorized for use with anterior nasal swab specimens collected using either: (1) the Color COVID-19 Self-Swab Collection Kit when used consistent with its authorization; or (2) the binx Health At-home Nasal Swab COVID-19 Sample Collection Kit when used consistent with its authorization.

Emergency use of this test is limited to the authorized laboratory.

Authorized Laboratory: Clinical Research Sequencing Platform (CRSP), LLC at the Broad Institute of MIT and Harvard located at 320 Charles Street, Cambridge, MA 02141 which is certified under Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, and meets requirements to perform high complexity tests.

Dear Dr. Lennon:
On March 5, 2021, based on your\(^1\) request, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for emergency use of the CRSP SARS-CoV-2 Real-time Reverse Transcriptase (RT)-PCR Diagnostic Assay (Version 3), pursuant to Section 564 of the Federal Food, Drug, and Cosmetic Act (the Act) (21 U.S.C. §360bbb-3) for the indications stated in the letter.\(^2\) Based on your request, FDA revised and reissued the letter on May 13, 2021.\(^3\) In addition, based on your notification pursuant to the April 20, 2021, pooling and serial testing amendment letter,\(^4\) FDA notified you of inclusion of your product under Exhibit 1 of the April 20, 2021, pooling and serial testing amendment.\(^5\) In addition, FDA established additional Conditions of Authorization in response to the continued emergence of new variants of SARS-CoV-2 on September 23, 2021.\(^6\)

On February 23, 2022, you requested to further revise your EUA. Based on that request, and having concluded that revising the May 13, 2021, EUA is appropriate to protect the public health or safety under section 564(g)(2)(C) of the Act (21 U.S.C. § 360bbb-3(g)(2)(C)), FDA is reissuing the May 13, 2021, letter in its entirety with the revisions incorporated.\(^7\)

\(^1\) For ease of reference, this letter will use the term “you” and related terms to refer to Clinical Research Sequencing Platform (CRSP), LLC at the Broad Institute of MIT and Harvard.

\(^2\) In the March 5, 2021, letter, the CRSP SARS-CoV-2 Real-time Reverse Transcriptase (RT)-PCR Diagnostic Assay (Version 3) was authorized for the following indications for use: (1) The qualitative detection of nucleic acid from SARS-CoV-2 in dry anterior nasal swabs from individuals suspected of COVID-19 by their healthcare provider. (2) The qualitative detection of nucleic acid from SARS-CoV-2 in dry anterior nasal swab specimens self-collected unsupervised using the CRSP Self-Swab kit, by individuals (18 years of age and older) suspected of COVID-19 by their healthcare provider and when determined to be appropriate by the healthcare provider. (3) For use with the Color COVID-19 Self-Swab Collection Kit for individuals (18 years of age and older) to self-collect anterior nasal swab specimens unsupervised at home or in a healthcare setting when determined to be appropriate by a healthcare provider. (4) For use with the Binx Health At-home Nasal Swab COVID-19 Sample Collection Kit for individuals (18 years of age and older) for self-collection of nasal swab specimens at home (which includes in a community-based setting), when determined by a healthcare provider to be appropriate based on the results of an online COVID-19 questionnaire. In addition, testing was limited to the Clinical Research Sequencing Platform (CRSP), LLC at the Broad Institute of MIT and Harvard located at 320 Charles Street, Cambridge, MA 02141 which is certified under Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, and meets requirements to perform high complexity tests.

\(^3\) On May 13, 2021, the revisions to the March 5, 2021, letter and authorized labeling included: (1) updates to the intended use with respect to the authorized collection kits for anterior nasal swab specimens to reflect language used in more recent authorizations and (2) minor updates to the Fact Sheet for Healthcare Providers and Fact Sheet for Individuals to reflect language used in more recent authorizations.

\(^4\) The Pooling and Serial Testing Amendment for Certain Molecular Diagnostic Tests for SARS-CoV-2 Letter – April 20, 2021, can be accessed at: https://www.fda.gov/media/147737/download

\(^5\) On June 15, 2021, inclusion of your product in Exhibit 1 was for the qualitative detection of RNA from SARS-CoV-2 in pooled samples containing up to 10 individual human anterior nasal swabs placed in a single vial containing transport media after being collected by a healthcare provider (HCP) or self-collected under the supervision of an HCP from individuals without symptoms or other reasons to suspect COVID-19, when tested as part of a serial testing program including testing at least once per week. Currently, your product continues to be listed under Exhibit 1 of this amendment, with all applicable requirements as described in the April 20, 2021, letter.

\(^6\) The Viral Mutation Revision Letter – September 23, 2021, can be accessed at: https://www.fda.gov/media/152406/download

\(^7\) The revisions to the May 13, 2021, letter and authorized labeling include: (1) updates to the intended use to expand the indicated population claims to include pediatrics (age 18 years and older (self-collected), 12 years and older (self-collected under adult supervision), or 2 years and older (collected with adult assistance)), (2) extension of the shelf life stability of the CRSP Self-Swab Kit to 120 hours, (3) update Instructions for Use (IFU) limitations to
section 564 of the Act and the Scope of Authorization (Section II) and Conditions of Authorization (Section IV) of this reissued letter, your product is now intended for the indications described above.

On February 4, 2020, pursuant to Section 564(b)(1)(C) of the Act, the Secretary of the Department of Health and Human Services (HHS) determined that there is a public health emergency that has a significant potential to affect national security or the health and security of United States citizens living abroad, and that involves the virus that causes COVID-19. Pursuant to Section 564 of the Act, and on the basis of such determination, the Secretary of HHS then declared that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of the virus that causes COVID-19 subject to the terms of any authorization issued under Section 564(a) of the Act.

FDA considered the totality of scientific information available in authorizing the emergency use of your product for the indication above. A summary of the performance information FDA relied upon is contained in the EUA Summary (identified below).

Having concluded that the criteria for issuance of this authorization under Section 564(c) of the Act are met, I am authorizing the emergency use of your product, described in the Scope of Authorization of this letter (Section II), subject to the terms of this authorization.

I. Criteria for Issuance of Authorization

I have concluded that the emergency use of your product meets the criteria for issuance of an authorization under Section 564(c) of the Act, because I have concluded that:

1. The SARS-CoV-2 can cause a serious or life-threatening disease or condition, including severe respiratory illness, to humans infected by this virus;

2. Based on the totality of scientific evidence available to FDA, it is reasonable to believe that your product may be effective in diagnosing COVID-19, and that the known and potential benefits of your product when used for diagnosing COVID-19, outweigh the known and potential risks of your product; and

3. There is no adequate, approved, and available alternative to the emergency use of your product.

satisfy the September 23, 2021, Viral Mutation Revision Letter requirements and the April 20, 2021 Pooling and Serial Testing Amendment for Certain Molecular Diagnostic Tests for SARS-CoV-2, (4) updates to the warnings and limitations in SOPs to comply with the Pooling and Serial Testing Amendment for Certain Molecular Diagnostic Tests for SARS-CoV-2, and (5) minor updates to the Fact Sheet for Healthcare Providers and Fact Sheet for Patients to reflect language used in more recent authorizations.

For ease of reference, this letter will use the term “your product” to refer to the CRSP SARS-CoV-2 Real-time Reverse Transcriptase (RT)-PCR Diagnostic Assay (Version 3) for the indication described above.


No other criteria of issuance have been prescribed by regulation under Section 564(c)(4) of the Act.
II. Scope of Authorization

I have concluded, pursuant to Section 564(d)(1) of the Act, that the scope of this authorization is limited to the indication above.

Authorized Product Details

Your product is a qualitative test for the detection of nucleic acid from SARS-CoV-2 in dry anterior nasal swabs from individuals suspected of COVID-19 by their healthcare provider.

Your product is also authorized for the qualitative detection of nucleic acid from SARS-CoV-2 in dry anterior nasal swab specimens collected using the CRSP Self-Swab kit, by individuals 18 years of age and older (self-collected), 14 years and older (self-collected under adult supervision), or 2 years and older (collected with adult assistance) suspected of COVID-19 by their healthcare provider and when determined to be appropriate by the healthcare provider. The kit is provided to individuals by the healthcare provider and the specimens collected using the CRSP Self-Swab kit will be dropped off at the designated location and transported via courier for testing at the Clinical Research Sequencing Platform (CRSP), LLC at the Broad Institute of MIT and Harvard.

Your product is also authorized for use with anterior nasal swab specimens collected using either: (1) the Color COVID-19 Self-Swab Collection Kit when used consistent with its authorization; or (2) the binx Health At-home Nasal Swab COVID-19 Sample Collection Kit when used consistent with its authorization.

All testing is limited to the Clinical Research Sequencing Platform (CRSP), LLC at the Broad Institute of MIT and Harvard, located at 320 Charles Street, Cambridge, MA 02141 which is certified under CLIA, 42 U.S.C. §263a, and meets requirements to perform high complexity tests.

The SARS-CoV-2 RNA is generally detectable in anterior nasal specimens during the acute phase of infection. Positive results are indicative of the presence of SARS-CoV-2 RNA; clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient management decisions. Negative results must be combined with clinical observations, patient history, and epidemiological information.

To use your product, SARS-CoV-2 nucleic acid is first extracted and purified from anterior nasal swab specimens. The purified nucleic acid is then reverse transcribed into cDNA followed by PCR amplification and detection using an authorized real-time (RT) PCR instrument. The CRSP SARS-CoV-2 Real-time Reverse Transcriptase (RT)-PCR Diagnostic Assay (Version 3) includes the materials (or other authorized materials as may be requested under Condition Q. below) described in the authorized labeling.

Your product requires control materials (or other authorized control materials as may be requested under Condition Q. below) that are described in the authorized labeling.
Your product also requires the use of additional authorized ancillary reagents that are not included with your product and are described in the authorized labeling.

The above described product is authorized to be accompanied with laboratory procedures (described below), the EUA Summary (available at https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas), and the following fact sheets pertaining to the emergency use, which are required to be made available to healthcare providers and patients:

- Fact Sheet for Healthcare Providers: Clinical Research Sequencing Platform (CRSP), LLC at the Broad Institute of MIT and Harvard - CRSP SARS-CoV-2 Real-time Reverse Transcriptase (RT)-PCR Diagnostic Assay (Version 3)
- Fact Sheet for Patients: Clinical Research Sequencing Platform (CRSP), LLC at the Broad Institute of MIT and Harvard - CRSP SARS-CoV-2 Real-time Reverse Transcriptase (RT)-PCR Diagnostic Assay (Version 3)

The above described product, when accompanied by the “CRSP SARS-CoV-2 Real-time Reverse Transcriptase (RT)-PCR Diagnostic Assay Testing and Calling Processes Assay Version 3 (V3)” SOP, “CRSP SARS-CoV2 Diagnostic Testing Sample Drop off and Inspection SOP”, “CRSP SARS-CoV2 Diagnostic and Pooled Testing Receipt and Accessioning SOP”, the EUA Summary (identified above), and the two Fact Sheets, is authorized to be used under this EUA, by the authorized laboratory, despite the fact that it does not meet certain requirements otherwise required by applicable federal law.

The CRSP Self-Swab Kit with the CRSP Self-Swab Kit instructions is authorized to be distributed and used as part of the above described product as set forth in this EUA.

“Authorized labeling” refers to “CRSP SARS-CoV-2 Real-time Reverse Transcriptase (RT)-PCR Diagnostic Assay Testing and Calling Processes Assay Version 3 (V3)” SOP, “CRSP SARS-CoV2 Diagnostic Testing Sample Drop off and Inspection SOP”, “CRSP SARS-CoV2 Diagnostic and Pooled Testing Receipt and Accessioning SOP”, the EUA Summary, the two Fact Sheets, and the CRSP Self-Swab Kit instructions.11

I have concluded, pursuant to Section 564(d)(2) of the Act, that it is reasonable to believe that the known and potential benefits of your product, when used consistent with the Scope of Authorization of this letter (Section II), outweigh the known and potential risks of your product.

I have concluded, pursuant to Section 564(d)(3) of the Act, based on the totality of scientific evidence available to FDA, that it is reasonable to believe that your product may be effective in diagnosing COVID-19, when used consistent with the Scope of Authorization of this letter (Section II), pursuant to Section 564(c)(2)(A) of the Act.

FDA has reviewed the scientific information available to FDA, including the information

---

11 The portions of authorized labeling that are within the scope of the April 20, 2021, amendment letter are not included within the scope of this letter of authorization, and therefore included for convenience in the authorized labeling (refer to footnote 4, 5).
supporting the conclusions described in Section I above, and concludes that your product (as
described in the Scope of Authorization of this letter (Section II)) meets the criteria set forth in
Section 564(c) of the Act concerning safety and potential effectiveness.

The emergency use of your product under this EUA must be consistent with, and may not
exceed, the terms of this letter, including the Scope of Authorization (Section II) and the
Conditions of Authorization (Section IV). Subject to the terms of this EUA and under the
circumstances set forth in the Secretary of HHS’s determination under Section 564(b)(1)(C) of
the Act described above and the Secretary of HHS’s corresponding declaration under Section
564(b)(1) of the Act, your product is authorized for the indication above.

III. Waiver of Certain Requirements

I am waiving the following requirements for your product during the duration of this EUA:

- Current good manufacturing practice requirements, including the quality system
  requirements under 21 CFR Part 820 with respect to the design, manufacture,
  packaging, labeling, distribution and storage of your product.

IV. Conditions of Authorization

Pursuant to Section 564(e) of the Act, I am establishing the following conditions on this
authorization:

Clinical Research Sequencing Platform (CRSP), LLC at the Broad Institute of MIT and
Harvard (You) and Authorized Distributor(s)12

A. Your product must comply with the following labeling requirements pursuant to FDA
regulations: the intended use statement (21 CFR 809.10(a)(2), (b)(2)); adequate
directions for use (21 U.S.C. 352(f)), (21 CFR 809.10(b)(5), (7), and (8)); appropriate
limitations on the use of the device including information required under 21 CFR
809.10(a)(4); and any available information regarding performance of the device,
including requirements under 21 CFR 809.10(b)(12).

B. You and authorized distributor(s) must make available on your website(s), if
applicable, the Fact Sheet for Healthcare Providers and the Fact Sheet for Patients.

C. You and authorized distributor(s) must inform relevant public health authorities of this
EUA, including the terms and conditions herein, and any updates made to your product
and authorized labeling.

D. You and authorized distributor(s) will collect information on the performance of your
product. You must report to FDA any suspected occurrence of false positive or false

12 “Authorized Distributor(s)” are identified by you, Clinical Research Sequencing Platform (CRSP), LLC at the
Broad Institute of MIT and Harvard, in your EUA submission as an entity allowed to distribute the CRSP Self-Swab
kit.
negative results and significant deviations from the established performance characteristics of your product of which you become aware.

E. You and authorized distributor(s) must make available all instructions related to the collection of anterior nasal swab specimens using the CRSP Self-Swab Kit, both in the shipped kit and on your website.

F. Through a process of inventory control, you and authorized distributor(s) must maintain records of the numbers and locations to which the CRSP Self-Swab Kit is distributed.

G. You and authorized distributor(s) must maintain customer complaint files on record. You will report to FDA any significant complaints about usability or deviations from the established performance characteristics of the CRSP Self-Swab Kit of which you become aware.

H. You and authorized distributor(s) are authorized to make available additional information relating to the emergency use of your product that is consistent with, and does not exceed, the terms of this letter of authorization.

I. You and authorized distributor(s) must ensure that any records associated with this EUA, including test usage, are maintained until otherwise notified by FDA. Such records must be made available to FDA for inspection upon request.

Clinical Research Sequencing Platform (CRSP), LLC at the Broad Institute of MIT and Harvard (You)

J. You must notify FDA of any authorized distributor(s) of the CRSP Self-Swab kit, including the name, address, and phone number of any authorized distributor(s).

K. You must provide authorized distributor(s) with a copy of this EUA and communicate to authorized distributor(s) any authorized revisions that might be made to this EUA and its authorized accompanying materials.

L. You must notify the relevant public health authorities of your intent to run your product.

M. You must have a process in place for reporting test results to healthcare providers and relevant public health authorities, as appropriate.

N. You must include with test result reports, all authorized Fact Sheets. Under exigent circumstances, other appropriate methods for disseminating these Fact Sheets may be used, which may include mass media.

O. You must use your product as outlined in the authorized labeling. Deviations from the authorized procedures, including the authorized instruments, authorized extraction methods, authorized clinical specimen types, authorized control materials, authorized
other ancillary reagents and authorized materials required to use your product are not permitted.

P. When testing authorized specimens collected using home-collection kits authorized for use with your product, you must follow any specimen accessioning protocols provided with the collection kit when accepting specimens for testing.

Q. You may request changes to this EUA for your product, including to the Scope of Authorization (Section II in this letter) or to the authorized labeling, including requests to make available additional authorized labeling specific to an authorized distributor. Such additional labeling may use another name for the product but otherwise must be consistent with the authorized labeling, and not exceed the terms of authorization of this letter. Any request for changes to this EUA should be submitted to the Division of Microbiology (DMD)/Office of Health Technology 7 (OHT7)-Office of In Vitro Diagnostics and Radiological Health (OIR)/Office of Product Evaluation and Quality (OPEQ)/Center for Devices and Radiological Health (CDRH) and require appropriate authorization from FDA prior to implementation.

R. You must evaluate the analytical limit of detection and assess traceability\(^\text{13}\) of your product with any FDA-recommended reference material(s), if requested by FDA. After submission to and concurrence with the data by FDA, FDA will update the EUA Summary to reflect the additional testing.

S. You must submit to FDA a summary report within 30 calendar days of authorization summarizing the results of any testing performed using specimens collected with the CRSP Self-Swab kit, Color COVID-19 Self-Swab Collection Kit and binx health At-home Nasal Swab COVID-19 Sample Collection Kit for use with your product during that timeframe, including how many specimens were received, how many specimens had to be rejected during accession and the main reasons for rejection, and the positivity rate for specimens collected with the authorized collection kit.

T. You must have a process in place to track adverse events, including any occurrence of false results with your product, including with the CRSP Self-Swab Kit, or any other home specimen collection kit authorized for use with your product, and report any such events to FDA in accordance with 21 CFR Part 803. Serious adverse events, especially unexpected biosafety concerns, should immediately be reported to DMD/OHT7-OIR/OPEQ/CDRH (via email: CDRH-EUA-Reporting@fda.hhs.gov).

U. All laboratory personnel using your product must be appropriately trained in RT-PCR techniques and use appropriate laboratory and personal protective equipment when handling this kit and use your product in accordance with the authorized labeling.

V. You must evaluate the impact of SARS-CoV-2 viral mutations on your product’s performance. Such evaluations must occur on an ongoing basis and must include any

\(^{13}\) Traceability refers to tracing analytical sensitivity/reactivity back to an FDA-recommended reference material.
additional data analysis that is requested by FDA in response to any performance concerns you or FDA identify during routine evaluation. Additionally, if requested by FDA, you must submit records of these evaluations for FDA review within 48 hours of the request. If your evaluation identifies viral mutations that affect the stated expected performance of your device, you must notify FDA immediately (via email: CDRH-EUA-Reporting@fda.hhs.gov).

W. If requested by FDA, you must update your labeling within 7 calendar days to include any additional labeling risk mitigations identified by FDA regarding the impact of viral mutations on test performance. Such updates will be made in consultation with, and require concurrence of, DMD/OHT7-OIR/OPEQ/CDRH.

**Conditions Related to Printed Materials, Advertising and Promotion**

X. All descriptive printed matter, advertising, and promotional materials relating to the use of your product shall be consistent with the authorized labeling, as well as the terms set forth in this EUA and meet the requirements set forth in section 502(a), (q)(1), and (r) of the Act, as applicable, and FDA implementing regulations.

Y. No descriptive printed matter, advertising, or promotional materials relating to the use of your product may represent or suggest that this test is safe or effective for the detection of SARS-CoV-2.

Z. All descriptive printed matter, advertising, and promotional materials relating to the use of your product shall clearly and conspicuously state that:

- This product has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA for use by the authorized laboratory;

- This product has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens; and

- The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

The emergency use of your product as described in this letter of authorization must comply with the conditions and all other terms of this authorization.

**V. Duration of Authorization**

This EUA will be effective until the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostics for detection and/or diagnosis of
COVID-19 is terminated under Section 564(b)(2) of the Act or the EUA is revoked under Section 564(g) of the Act.

Sincerely,

____________________________
Jacqueline A. O’Shaughnessy, Ph.D.
Acting Chief Scientist
Food and Drug Administration

Enclosure